China Health Industries Holdings, Inc. Reports Earnings Results for the Second Quarter Ended December 31, 2019
February 14, 2020 at 11:01 am
Share
China Health Industries Holdings, Inc. announced earnings results for the second quarter ended December 31, 2019. For the second quarter, the company announced sales was USD 3.421 million compared to USD 2.714 million a year ago. Operating income was USD 1.951 million compared to USD 1.477 million a year ago. Net income was USD 1.426 million compared to USD 1.117 million a year ago. Basic earnings per share from continuing operations was USD 0.0218 compared to USD 0.017 a year ago. For the half year, sales was USD 5.475 million compared to USD 4.855 million a year ago. Operating income was USD 2.990 million compared to USD 2.389 million a year ago. Net income was USD 2.183 million compared to USD 1.749 million a year ago. Basic earnings per share from continuing operations was USD 0.0333 compared to USD 0.0267 a year ago. Diluted earnings per share from continuing operations was USD 0.033 compared to USD 0.027 a year ago.
China Health Industries Holdings, Inc. is a manufacturer of health food products. The Company's principal business operations are conducted through its subsidiaries: Harbin Humankind Biology Technology Co., Limited (Humankind) and Heilongjiang Huimeijia Pharmaceutical Co., Ltd (HLJ Huimeijia). The Company has three operating segments: Humankind, HLJ Huimeijia and others. Humankind is engaged in the manufacturing and sale of health products. HLJ Huimeijia is engaged in the manufacturing and distribution of tincture; ointments; rubber paste, including hormones; topical solution, suppositories, liniment, including traditional Chinese medicine extractions; enemas, and oral liquids. As of June 30, 2016, the Company, through Humankind manufactured and sold 14 health supplement products. As of June 30, 2016, the Company, through HLJ Huimeijia manufactured and sold 21 products. The Company's products are sold through sales agents.